Cargando…

Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds

The rise of SARS-CoV-2 variants has made the pursuit to define correlates of protection more troublesome, despite the availability of the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used to standardise laboratory findings into an inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantoni, Diego, Mayora-Neto, Martin, Nadesalingam, Angalee, Wells, David A., Carnell, George W., Ohlendorf, Luis, Ferrari, Matteo, Palmer, Phil, Chan, Andrew C.Y., Smith, Peter, Bentley, Emma M., Einhauser, Sebastian, Wagner, Ralf, Page, Mark, Raddi, Gianmarco, Baxendale, Helen, Castillo-Olivares, Javier, Heeney, Jonathan, Temperton, Nigel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940306/
https://www.ncbi.nlm.nih.gov/pubmed/35330908
http://dx.doi.org/10.3389/fimmu.2022.773982
_version_ 1784672902458638336
author Cantoni, Diego
Mayora-Neto, Martin
Nadesalingam, Angalee
Wells, David A.
Carnell, George W.
Ohlendorf, Luis
Ferrari, Matteo
Palmer, Phil
Chan, Andrew C.Y.
Smith, Peter
Bentley, Emma M.
Einhauser, Sebastian
Wagner, Ralf
Page, Mark
Raddi, Gianmarco
Baxendale, Helen
Castillo-Olivares, Javier
Heeney, Jonathan
Temperton, Nigel
author_facet Cantoni, Diego
Mayora-Neto, Martin
Nadesalingam, Angalee
Wells, David A.
Carnell, George W.
Ohlendorf, Luis
Ferrari, Matteo
Palmer, Phil
Chan, Andrew C.Y.
Smith, Peter
Bentley, Emma M.
Einhauser, Sebastian
Wagner, Ralf
Page, Mark
Raddi, Gianmarco
Baxendale, Helen
Castillo-Olivares, Javier
Heeney, Jonathan
Temperton, Nigel
author_sort Cantoni, Diego
collection PubMed
description The rise of SARS-CoV-2 variants has made the pursuit to define correlates of protection more troublesome, despite the availability of the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used to standardise laboratory findings into an international unitage. Using pseudotyped virus, we examine the capacity of convalescent sera, from a well-defined cohort of healthcare workers (HCW) and Patients infected during the first wave from a national critical care centre in the UK to neutralise B.1.1.298, variants of interest (VOI) B.1.617.1 (Kappa), and four VOCs, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta), including the B.1.617.2 K417N, informally known as Delta Plus. We utilised the WHO International Standard for anti-SARS-CoV-2 Immunoglobulin to report neutralisation antibody levels in International Units per mL. Our data demonstrate a significant reduction in the ability of first wave convalescent sera to neutralise the VOCs. Patients and HCWs with more severe COVID-19 were found to have higher antibody titres and to neutralise the VOCs more effectively than individuals with milder symptoms. Using an estimated threshold for 50% protection, 54 IU/mL, we found most asymptomatic and mild cases did not produce titres above this threshold.
format Online
Article
Text
id pubmed-8940306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89403062022-03-23 Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds Cantoni, Diego Mayora-Neto, Martin Nadesalingam, Angalee Wells, David A. Carnell, George W. Ohlendorf, Luis Ferrari, Matteo Palmer, Phil Chan, Andrew C.Y. Smith, Peter Bentley, Emma M. Einhauser, Sebastian Wagner, Ralf Page, Mark Raddi, Gianmarco Baxendale, Helen Castillo-Olivares, Javier Heeney, Jonathan Temperton, Nigel Front Immunol Immunology The rise of SARS-CoV-2 variants has made the pursuit to define correlates of protection more troublesome, despite the availability of the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used to standardise laboratory findings into an international unitage. Using pseudotyped virus, we examine the capacity of convalescent sera, from a well-defined cohort of healthcare workers (HCW) and Patients infected during the first wave from a national critical care centre in the UK to neutralise B.1.1.298, variants of interest (VOI) B.1.617.1 (Kappa), and four VOCs, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta), including the B.1.617.2 K417N, informally known as Delta Plus. We utilised the WHO International Standard for anti-SARS-CoV-2 Immunoglobulin to report neutralisation antibody levels in International Units per mL. Our data demonstrate a significant reduction in the ability of first wave convalescent sera to neutralise the VOCs. Patients and HCWs with more severe COVID-19 were found to have higher antibody titres and to neutralise the VOCs more effectively than individuals with milder symptoms. Using an estimated threshold for 50% protection, 54 IU/mL, we found most asymptomatic and mild cases did not produce titres above this threshold. Frontiers Media S.A. 2022-03-07 /pmc/articles/PMC8940306/ /pubmed/35330908 http://dx.doi.org/10.3389/fimmu.2022.773982 Text en Copyright © 2022 Cantoni, Mayora-Neto, Nadesalingam, Wells, Carnell, Ohlendorf, Ferrari, Palmer, Chan, Smith, Bentley, Einhauser, Wagner, Page, Raddi, Baxendale, Castillo-Olivares, Heeney and Temperton https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Cantoni, Diego
Mayora-Neto, Martin
Nadesalingam, Angalee
Wells, David A.
Carnell, George W.
Ohlendorf, Luis
Ferrari, Matteo
Palmer, Phil
Chan, Andrew C.Y.
Smith, Peter
Bentley, Emma M.
Einhauser, Sebastian
Wagner, Ralf
Page, Mark
Raddi, Gianmarco
Baxendale, Helen
Castillo-Olivares, Javier
Heeney, Jonathan
Temperton, Nigel
Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
title Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
title_full Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
title_fullStr Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
title_full_unstemmed Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
title_short Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
title_sort neutralisation hierarchy of sars-cov-2 variants of concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940306/
https://www.ncbi.nlm.nih.gov/pubmed/35330908
http://dx.doi.org/10.3389/fimmu.2022.773982
work_keys_str_mv AT cantonidiego neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT mayoranetomartin neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT nadesalingamangalee neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT wellsdavida neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT carnellgeorgew neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT ohlendorfluis neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT ferrarimatteo neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT palmerphil neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT chanandrewcy neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT smithpeter neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT bentleyemmam neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT einhausersebastian neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT wagnerralf neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT pagemark neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT raddigianmarco neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT baxendalehelen neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT castilloolivaresjavier neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT heeneyjonathan neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds
AT tempertonnigel neutralisationhierarchyofsarscov2variantsofconcernusingstandardisedquantitativeneutralisationassaysrevealsacorrelationwithdiseaseseveritytowardsdecipheringprotectiveantibodythresholds